Neurology Research Models and Services

Highly relevant neurology models to facilitate preclinical drug development

Drug development for neurodegenerative diseases is currently limited by poor translation of preclinical animal models to clinical application in humans. This results in extremely costly late-stage development failures and a lack of innovative treatments that halt or reverse disease progression in this field.  

InnoSer’s neurology team continues to expand upon our offerings that allow industry innovators to better understand the complexity of neurological disease and the effects of their compounds. We offer a selection of in vitro, ex vivo and in vivo models for testing new and innovative compounds within the challenging research area of neurodegenerative diseases. In addition, our team has expertise in neuromuscular disease studies. 

We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis. 

Valuable aspects of InnoSer’s neurology pipelines:

  • Centralized research with our full-service drug development options
  • Optimal study design and execution by experts
  • A full suite of (digital) histopathology assessments

In Vitro

We offer in vitro models and assays with cell lines and primary mouse cell types, including monocultures and mixed cultures of neuronal and glial cells. In addition, ex vivo brain slice culture assays allow investigation of therapeutic efficacy in the brain microenvironment. Our in vitro and ex vivo assays, and models allow you to investigate the effect of your investigational compound on specific neurological pathways. 

Models of alzheimer’s disease, parkinson’s disease, multiple sclerosis:

  • Stimulus (e.g., LPS, IL-13, Rotenone, etc.) 
  • Disease related peptides fis (e.g., β-amyloid, MBP, α-synuclein, etc.) 
  • Neurotoxins (AO, H2O2, 6-OHDA, Rotenone, etc.)

Readouts: 

  • Neuro-inflammation
  • Phagocytosis
  • Apoptosis and necrosis 
  • Cell metabolism  
  • Live cell imaging (Incucyte)  
  • Immunocytochemistry 
  • Analysis of NO, ROS, cytokines, …  
  • Meso Scale Discovery  
  • Neurodegeneration panels (Aβ38, Aβ40, Aβ42, APP, α-Synuclein Contactin-2/TAG-1, Neprilysin, Neuronal pentraxin-1, Tau) 

Ex Vivo

Preserving the spatial relationship between cellular types within a relevant tissue architecture, our ex vivo capabilities allow drug developers to examine the therapeutic effects of their test compounds in a relevant brain environment. We offer flexible research options including long-term culturing, tunable disease mimicking and therapeutic trials in a system without blood brain barrier (BBB) interference. 

Models of alzheimer’s disease, parkinson’s disease, multiple sclerosis:

  • Stimulus (e.g., LPS, IL-13, Rotenone, etc.) 
  • Disease related peptides fis (e.g., β-amyloid, MBP, α-synuclein, etc.) 
  • Neurotoxins (AO, H2O2, 6-OHDA, Rotenone, etc.)

Readouts: 

  • Live imaging 
  • Cell-cell interactions 
  • Cell migration
  • Examination of neuro-inflammation and neuroprotection
  • Demyelination/Remyelination
  • Immunohistochemistry 

In Vivo

Gain relevant insights into gene function using validated in vivo models. We offer a selection of transgenic mouse models to screen for novel drug candidates. 

ARTE10 (APP-PS1):

  • Prolonged evaluation of amyloid-lowering or –modifying therapies
  • Age-associated cognitive deficits
  • Neuroinflammation (reactive gliosis surrounding amyloid plaques has been reported) 

APPSWE Tg2576:

  • APP expression and amyloid plaque formation
  • Neuronal decline and memory loss associated with AD
  • Study of drugs designed for treatment or prevention of AD 

Tau P301L:

  • Studying AD, Pick’s disease and other neurological syndromes associated with NFT

Readouts & Analyses:

  • Stereotactic delivery of surgery
  • Intracranial cell transplantation
  • Full suite of histopathology services e.g. Immunohistochemistry of brain and nerve tissues (IHC) 
  • Bioanalyses in various biological matrices 
  • Flow Cytometry 
  • ELISA, Ultra-Sensitive ELISA for CSF/plasma biomarkers 
  • Meso Scale Discovery (MSD) 
  • Immunoblotting 

AAALAC Accreditation

InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

AAALAC logo

Animal Welfare

The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

References

  • Beeken J, Kessels S, Rigo J.-M, Alpizar Y.A, Nguyen L, Brône B. p27kip1 Modulates the Morphology and Phagocytic Activity of Microglia. Int. J. Mol. Sci. 2022, 23, 10432. doi: 10.3390/ijms231810432

Related Resources

Facility Management

Mouse Models Overview

Introducing InnoSer's Acceleration Program (ISAP)

Need more information?

If you have any questions about how we can help you answer your research questions, then let us know.